ChemoCentryx Inc. (CCXI) Starts Presentation at B. Riley Conference
ChemoCentryx (NASDAQ: CCXI), is a biopharmaceutical company developing new medications targeted at inflammatory and autoimmune diseases and cancer. ChemoCentryx targets the chemokine and chemoattractant systems to discover, develop and commercialize orally administered therapies. ChemoCentryx is currently focusing on its late-stage drug candidates for patients with rare diseases, avacopan (CCX168) and CCX140. Avacopan is in phase III development for the treatment of ANCA-associated Vasculitis. The company's other late-stage drug candidate is CCX140, an inhibitor of the chemokine receptor known as CCR2, which is currently being developed for patients with focal segmental glomerulosclerosis (FSGS), a debilitating kidney disease. The U.S. Food and…